Ibuprofen API Market

Ibuprofen API Market Outlook for 2024 to 2034

Recently proposed data on the ibuprofen API market analysis demonstrates that demand for ibuprofen APIs is valued at around USD 665 million in 2024 and is on its way to register a CAGR of 2.5% to reach USD 851 million by 2034. The evolving landscape in emerging economies propels the demand boost in the API sector, shaping the pharmaceutical metamorphosis.

Attributes	Details
Market Value for 2024	USD 665 million
Market Value for 2034	USD 851 million
Market Forecast CAGR for 2024 to 2034	2.5%

Consumption Analysis of Ibuprofen APIs

• Demand for ibuprofen APIs is rising as the incidence of chronic diseases such as rheumatoid arthritis and migraine increases in developing nations.
• Prominent and emerging pharmaceutical and biochemical organizations are investing their resources in the research and development of ibuprofen APIs. Medications featuring these APIs are available in the form of tablets, capsules, and syrups.
• Geriatric patients form a widespread consumer base for ibuprofen APIs. As a non-steroidal anti-inflammatory drug, it aids in relieving pain, reducing fever, and decreasing inflammation.
• Biopharmaceutical companies compelled by the need for ibuprofen APIs are innovating these API supplements. This is because the drug is used to treat illnesses such as upset stomach, gastrointestinal bleeding, and kidney damage.
• Various methods for developing a synthetic route to ibuprofen are being considered to enhance market growth and provide an optimistic outlook for the Ibuprofen raw material market.

Historical Performance and Future Growth of the Ibuprofen API Market

Demand is presumed to limit the market growth. The historical CAGR of 3.0% was recorded for the market and a 2.5% CAGR is calculated through 2034.

Attributes	Details
Market Historical CAGR for 2019 to 2023	3.0%

The synthesis of ibuprofen APIs has environmental drawbacks due to revised production guidelines, affecting manufacturers' costs and raw material sourcing. This has led to a downturn in the market, as the drug requires high production value.

Key aspects to influence the demand through 2034 include:

• Top pharmaceutical and medical producers are primarily focused on researching and developing synthetic ibuprofen APIs in more environmentally friendly ways.
• Opportunities to increase demand exist by introducing improved technologies such as bioinformatics, high-throughput methods, and combinatorial chemistry, which are expected to encourage sales in the next decade.

Market players need to be prudent and flexible over the anticipated period, as these challenging attributes position the industry for success in the subsequent decade.

Key Trends Influencing the Ibuprofen API Market

Female Patients Creates a Huge Demand

• Ibuprofen is used to treat menstrual discomfort, particularly dysmenorrhea, which can impede the physical activity of females. Hence, sales of the drug's APIs are expected to develop in the forthcoming decade.
• According to the World Health Organization, menstruation impacts around 1.8 billion individuals globally, with 800 million women and girls experiencing it daily, accounting for 26% of the global population.
• Active pharmaceutical ingredients like analgesics, antipyretics, and anti-inflammatories are used in its manufacturing, creating demand by reducing pain, fever, and inflammation.
• Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are often used to relieve menstrual discomfort by blocking prostaglandins and reducing pain.

The Pharmaceutical and Biochemical Industry Rife Ibuprofen Depletion

• Pharmaceutical and biochemical organizations cater to the demand as they relieve pain, swelling, and fever.
• The increasing prevalence of various illnesses globally, including heart disorders, infections, diabetes, and kidney issues, drives drug development in pharmaceutical and biochemical corporations.
• API drug shortages, task forces, cost-effective drug manufacturing, and supply to developed nations influence the global market and encourage pharmaceutical and biochemical production growth.

Demand for Arthritis Medication Rumbles the Growth Rate

• Arthritis is pain experienced in joints, characterized by stiffness, warmth, swelling, redness, and discomfort due to inflammation. The increasing burden of arthritis, coupled with its rising occurrence as people age, is closely linked to the high demand for ibuprofen as a pain relief solution.
• Rheumatoid arthritis, an autoimmune disease causing joint inflammation and pain, is treated with ibuprofen, a pain reliever with superior tolerability and safety compared to aspirin and other NSAIDs. The growing demand for pain relief medications in pediatric arthritis patients is foreseen to propel the ibuprofen API market.

Category-wise Insights

Contract Manufacturing Organization Captures Around 55.3% of Market Share

Attributes	Details
Top End User	Contract Manufacturing Organization
Market share in 2024	55.30%

Demand from contract manufacturing organizations (CMOs) is significant, acquiring a market share of 55.6% in 2024. The following aspects contribute to the development of demand from contract manufacturing organizations:

• Contract manufacturing organizations are adapting their strategies to meet the evolving dynamics of the pharmaceutical sector, focusing on cost-cutting and differentiation. Major pharmaceutical companies favor them for API and final formulation manufacturing.
• Contract manufacturing organizations are integrating into pharmaceutical supply chains by collaborating with other regional and local CMOs to offer bundled services, enriching the sales of ibuprofen APIs.
• Contract manufacturers invest in research and development and incur production costs to compete, especially for ibuprofen.
• Demand for ibuprofen active pharmaceutical ingredient is increasing due to the presence of various disorders, leading to an increase in sales.

Country-wise Insights

According to derived data, demand from European countries to augment the sales growth in the forthcoming decade. The industry in France and Germany is developing steeply. The ibuprofen drug substance industry in Canada to register the subordinate CAGR compared to European competitors. Demand in Italy and Spain to remain moderate throughout.

Countries	CAGR from 2024 to 2034
Spain	3.7%
Germany	2.7%
Italy	3.3%
Canada	2.0%
France	3.0%

Spanish Pharmaceutical Companies Innovates the Ibuprofen API Industry

Through 2034, the industry in Spain is anticipated to register a 3.7% CAGR, owing to the development of prominent and emerging pharmaceutical and biopharma organizations.

• The demand for ibuprofen drug substance is foreseen to dwell in the Spanish supply chain operations.
• The streamlined operation of Spanish pharmaceutical industries presents growth opportunities for ibuprofen API manufacturing.

Chronic Illnesses of German Populace Demands Pharma Grade Ibuprofen API

Demand is projected to report a CAGR of 2.7% in Germany through 2034, due to the rising prevalence of chronic diseases such as arthritis and osteoporosis.

• As it is commonly considered a self-medicated drug, the demand for ibuprofen API has developed in the German healthcare infrastructure.
• Although this API seems promising, the German health regulatory bodies plummeted the growth rate.

Italian Geriatric Populations Desires for NSAID API

Demand in Italy is anticipated to showcase a CAGR of 3.3% between 2024 and 2034 as geriatric patients grow nationwide.

• Based on global geriatric populations, Italy registers ninth ranking, with approximately 60.34 million elderly population. The demand for different NSAID APIs is significant in the early care sector as it helps with pain, swelling, and fever.
• The Italian medical supply chain outlets provide easy access to self-medicated ibuprofen to improve older people's convenience.

French Women Healthcare Supports the Sales Growth

Demand in France is projected to report a CAGR of 3.0% from 2024 to 2034, as women desire demand for ibuprofen API to ease menstruation pain.

• The country’s need is experiencing development due to its favor in maternal care, particularly in relieving pain in arthritis and menstruation discomfort.
• The medical community is promoting its usage in healthcare environments, with France’s ibuprofen API market growth forced by its potential to close a specific ductus in newborns.

Climate Shift in Canada Promotes the Sales Growth

Sales is developing rapidly in Canada, witnessing a CAGR of 2.0% through 2034, owing to regular climate change in Canada.

• The unvarying climate change in Canada develops illnesses such as fever, headache, and joint pain, developing the demand.
• Ibuprofen's quick treatment has gained medical confidence, and the Canadian demand transition is foreseen due to advancements in medical treatments and pain control research.

Market Players Shaping the Outlook of the Global Ibuprofen API Market

Ibuprofen pharmaceutical ingredient suppliers are merging with CMOs to enhance raw material supply and streamline manufacturing processes, resulting in cost savings and improved time efficiency.

The pharmaceutical API sector is experiencing a surge in mergers and acquisitions, driven by companies seeking therapeutic, pipeline, and global expansion goals. These strategies are gaining popularity due to their significant benefits.

Pooling resources allows companies to create economies of scale, reduce costs, and increase efficiency, especially in product development. Mergers and acquisitions extend market share and help reach new customers for long-term growth.

Mergers and acquisitions are a key growth strategy in the industry, enabling companies to maintain competitiveness, expand globally, and enhance their raw material supply.

Recent Developments in the Ibuprofen API Market

• In May 2023, Ludhiana-based IOL Chemicals and Pharmaceuticals Limited, a leading pharmaceutical APIs and specialty chemical manufacturer, received the European Directorate for the Quality of Medicines & HealthCare's Certificate of Suitability.
• In November 2022, Solara Active Pharma Sciences received European Approval for its Vizag facility in Andhra Pradesh, marking the first international regulatory approval for manufacturing.
• In December 2020, BioSyent Pharma Inc. started shipments of Combogesic, the first fixed-dose combination of acetaminophen and ibuprofen in a single tablet in Canada, for short-term pain management and fever reduction.

Key Companies

• BASF SE
• BIOCAUSE Inc.
• IOL Chemicals And Pharmaceuticals Limited
• SI Group, Inc.
• Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd.
• Solara Active Pharma Sciences Limited
• Granules India Limited

Key Coverage in the Ibuprofen API Market Report

• Rising Growth of the Pharmaceutical Ingredient in the United States
• Growth Analysis of the Superfoods in Ibuprofen APIs
• Top 10 Emerging Trends in the Ibuprofen API market
• Analysis of Overview of Pharmaceutical Intermediate Market in the United States
• Sales Assessment of Market Dynamics of Active Pharmaceutical Ingredient Industry

Key Segments

By End User:

• Contract Manufacturing Organizations
• Pharmaceutical Companies

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa

Frequently Asked Questions

How Big is the Ibuprofen API Market?

The market is valued at USD 665 million in 2024.

What is the Future Forecast for the Ibuprofen API Market?

The market is anticipated to be valued at USD 861.3 million by 2034.

What is the Size of the Ibuprofen API Market in Canada?

In Canada, demand is anticipated to develop at a CAGR of 2.0% through 2034.

What is the Projected Growth Rate for the Ibuprofen API Industry?

The market is projected to register a CAGR of 2.50% from 2024 to 2034.

Who is the Supplier of Ibuprofen API?

The contract manufacturing organizations develops demand for ibuprofen APIs with a 55.3% market share in 2024.